Karah Parschauer's Insider Trades & SAST Disclosures
Karah Parschauer's most recent trade in Evolus Inc was a trade of 12,888 Common Stock done at an average price of $13.0 . Disclosure was reported to the exchange on March 12, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Karah Parschauer.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Evolus Inc | Karah Parschauer | Director | Sale of securities on an exchange or to another person at price $ 12.99 per share. | 12 Mar 2025 | 12,888 | 32,183 (0%) | 0% | 13.0 | 167,465 | Common Stock |
| Evolus Inc | Karah Parschauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2025 | 11,146 | 11,146 | - | - | Stock Option (Right to Buy) | |
| Evolus Inc | Karah Parschauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2025 | 7,364 | 45,071 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 18,443 | 88,133 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 42.10 per share. | 01 Mar 2025 | 12,846 | 75,287 (0%) | 0% | 42.1 | 540,817 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 26,074 | 26,074 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 14,494 | 69,690 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 42.93 per share. | 27 Feb 2025 | 2,230 | 55,751 (0%) | 0% | 42.9 | 95,734 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 42.75 per share. | 27 Feb 2025 | 760 | 54,991 (0%) | 0% | 42.8 | 32,490 | Common Stock |
| Tenaya Therapeutics Inc | Karah Parschauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Oct 2024 | 34,000 | 34,000 | - | - | Stock Option (Right to buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 12 Jun 2024 | 9,806 | 57,981 (0%) | 0% | 45 | 441,270 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 31,400 | 31,400 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 17,800 | 69,782 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 53.76 per share. | 01 Mar 2024 | 3,756 | 67,340 (0%) | 0% | 53.8 | 201,923 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 957 | 70,739 (0%) | 0% | 0 | Common Stock | |
| Evolus Inc | Parschauer Karah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 9,377 | 9,377 | - | - | Stock Option (Right to Buy) | |
| Evolus Inc | Parschauer Karah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 6,464 | 37,707 (0%) | 0% | 0 | Common Stock | |
| Evolus Inc | Karah Parschauer | Director | Sale of securities on an exchange or to another person at price $ 13.14 per share. | 30 Jan 2024 | 11,931 | 31,243 (0%) | 0% | 13.1 | 156,733 | Common Stock |
| Tenaya Therapeutics Inc | Karah Parschauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 29,532 | 29,532 | - | - | Stock Option (Right to buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 04 May 2023 | 4,378 | 51,982 (0%) | 0% | 45 | 197,010 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 39,400 | 39,400 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 22,000 | 59,101 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 45.25 per share. | 01 Mar 2023 | 3,161 | 56,139 (0%) | 0% | 45.2 | 143,035 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 2,663 | 37,101 (0%) | 0% | 0 | Common Stock | |
| Evolus Inc | Karah Parschauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2023 | 11,789 | 11,789 | - | - | Stock Option (Right to Buy) | |
| Evolus Inc | Karah Parschauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2023 | 8,293 | 43,174 (0%) | 0% | 0 | Common Stock | |
| Anebulo Pharmaceuticals Inc | Karah Parschauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2022 | 30,425 | 30,425 | - | - | Stock Option (right to buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 62.95 per share. | 07 Mar 2022 | 5,140 | 34,438 (0%) | 0% | 63.0 | 323,563 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 24,900 | 24,900 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 14,000 | 39,578 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 66.62 per share. | 01 Mar 2022 | 2,886 | 25,472 (0%) | 0% | 66.6 | 192,265 | Common Stock |
| Evolus Inc | Karah Parschauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 22,727 | 22,727 | - | - | Stock Option (Right to Buy) | |
| Evolus Inc | Karah Parschauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 15,568 | 34,881 (0%) | 0% | 0 | Common Stock | |
| Tenaya Therapeutics Inc | Karah Parschauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2021 | 19,495 | 19,495 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 81.14 per share. | 14 Oct 2021 | 310 | 28,358 (0%) | 0% | 81.1 | 25,153 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 100.65 per share. | 08 Sep 2021 | 7,336 | 28,668 (0%) | 0% | 100.6 | 738,368 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Sep 2021 | 7,336 | 17,664 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.50 per share. | 08 Sep 2021 | 7,336 | 36,004 (0%) | 0% | 54.5 | 399,812 | Common Stock |
| Arcturus Therapeutics Hold... | Karah Parschauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 113.67 per share. | 06 May 2021 | 313 | 29,997 (0%) | 0% | 113.7 | 35,579 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 11,000 | 11,000 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 5,500 | 29,561 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 4,636 | 34,197 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 138.17 per share. | 01 Mar 2021 | 3,970 | 30,227 (0%) | 0% | 138.2 | 548,535 | Common Stock |
| Evolus Inc | Karah Parschauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 19,313 | 19,313 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.50 per share. | 30 Oct 2020 | 9,903 | 33,871 (0%) | 0% | 54.5 | 539,714 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 100.12 per share. | 30 Oct 2020 | 9,903 | 24,061 (0%) | 0% | 100.1 | 991,488 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2020 | 9,903 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 100.00 per share. | 28 Oct 2020 | 97 | 23,968 (0%) | 0% | 100 | 9,700 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.51 per share. | 28 Oct 2020 | 97 | 24,065 (0%) | 0% | 54.5 | 5,287 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2020 | 97 | 34,903 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 88.00 per share. | 14 Oct 2020 | 325 | 23,968 (0%) | 0% | 88 | 28,600 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 95.00 per share. | 08 Oct 2020 | 10,000 | 24,293 (0%) | 0% | 95 | 950,000 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2020 | 10,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.50 per share. | 08 Oct 2020 | 10,000 | 34,293 (0%) | 0% | 54.5 | 545,000 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 90.00 per share. | 06 Oct 2020 | 10,000 | 24,293 (0%) | 0% | 90 | 900,000 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2020 | 10,000 | 17,000 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 48.43 per share. | 06 Oct 2020 | 10,000 | 34,293 (0%) | 0% | 48.4 | 484,300 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 85.00 per share. | 23 Sep 2020 | 10,000 | 24,293 (0%) | 0% | 85 | 850,000 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Sep 2020 | 10,000 | 27,000 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 48.43 per share. | 23 Sep 2020 | 10,000 | 34,293 (0%) | 0% | 48.4 | 484,300 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2020 | 10,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 88.44 per share. | 17 Aug 2020 | 10,000 | 26,663 (0%) | 0% | 88.4 | 884,400 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.50 per share. | 17 Aug 2020 | 10,000 | 36,663 (0%) | 0% | 54.5 | 545,000 | Common Stock |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 88.39 per share. | 17 Aug 2020 | 2,370 | 24,293 (0%) | 0% | 88.4 | 209,484 | Common Stock |
| Arcturus Therapeutics Hold... | Karah Parschauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2020 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Ultragenyx Pharmaceutical ... | Karah Parschauer | EVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.22 per share. | 20 Jun 2020 | 649 | 26,663 (0%) | 0% | 78.2 | 50,765 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges